If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽,分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰,使其能够同时与葡萄糖依赖性促胰岛素多肽(GIP)受体和胰高血糖素样肽-1(GLP-1)受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道,随后进入糖尿病与体重管理领域的临床研究。
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成修饰肽 | 39 个氨基酸,含脂肪酸侧链 |
| 受体靶点 | GIP 与 GLP-1 受体 | 双重激动剂 |
| 分子量 | 约 4.8 kDa | 以游离肽计 |
| 外观 | 白色至类白色粉末 | 冻干形态常见 |
| 溶解性 | 可溶于水及水性缓冲液 | 溶解后宜低温保存 |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
In electrical synapses, the presynaptic and postsynaptic cell membranes are connected by special channels called gap junctions that are capable of facilitating the direct flow of electrical current without the need for neurotransmitters, causing voltage changes in the presynaptic cell to induce voltage changes in the postsynaptic cell. In chemical synapses, the activation of voltage-gated calcium channels in the presynaptic neuron results in the release of neurotransmitters into the synaptic cleft, which thereafter bind to receptors located in the plasma membrane of the postsynaptic cell. The neurotransmitter may initiate an electrical response or a secondary messenger pathway that may either excite or inhibit the postsynaptic neuron. Chemical synapses can be classified according to the neurotransmitter released: glutamatergic (often excitatory), GABAergic (often inhibitory), cholinergic (e.g. vertebrate neuromuscular junction), and adrenergic (releasing norepinephrine). Depending on their release location, the receptors they bind to, and the ionic circumstances they encounter, various transmitters can be either excitatory or inhibitory. For instance, acetylcholine can either excite or inhibit depending on the type of receptors it binds to. In excitatory synapses, an influx of Na+ driven by excitatory neurotransmitters opens cation channels, enhancing the probability of depolarization in postsynaptic neurons and the initiation of an action potential.
While results vary slightly across reputable studies, the consensus is that the mean human penis, when erect, is in the range 5–6 in (13–15 cm) in length. The 2015 review (measured by staff) found average flaccid, stretched, and erect lengths of 9.16 cm (3.61 in), 13.24 cm (5.21 in), and 13.12 cm (5.17 in), respectively, and average flaccid and erect circumferences of 9.31 cm (3.67 in) and 11.66 cm (4.59 in), respectively. Erect length in the studies was measured by pushing the pre-pubic fat pad to the bone, and flaccid or erect girth (circumference) was measured at the base or mid-shaft of the penis.
The plan was for existing TA units to recruit over their establishments (aided by an increase in pay for Territorials, the removal of restrictions on promotion, which had hindered recruiting, construction of better-quality barracks and an increase in supper rations) and then form second-line divisions from cadres that could be increased. The total strength of the TA was to be 440,000: the field force of the Territorial Army was to rise from 130,000 to 340,000, organized in 26 divisions, while an additional 100,000 all ranks would form the anti-aircraft section. The forming Second Line formations were given liberty to be numbered and named as they saw fit, with some using related names and numbers from the First World War e.g. the 23rd (Northumbrian) Infantry Division formed in 1939. The immediate response to this announcement was a vast surge in recruiting with 88,000 men enlisted by the end of April. The London Rifle Brigade raised a second battalion in 24 hours. On 26 April, limited conscription was introduced. This resulted in 34,500 twenty-year-old militiamen being conscripted into the regular army, initially to be trained for six months before deployment to the forming second-line units. In parallel, recruits continued to surge into the Territorial Army but there were grave shortages of instructors and equipment. It was envisioned that the duplicating process and recruiting the required numbers of men would take no more than six months.
Sources: en.wikipedia.org
A helium mass spectrometer or helium leak detector are unique instruments commonly used to detect and locate small leaks. The helium leak detector was initially developed in the Manhattan Project during World War II to find extremely small leaks in the gas diffusion process of uranium enrichment plants. Typically, the test method uses a vacuum chamber, at vacuum pressures typically less than 100mTorr, in which a helium pressurized system under test is placed. Helium leaks out of the system under test, with the rate of leakage detected by an optimal ion source mass spectrometer or leak detector.
=== Contraindications === A few contraindications should be taken into account for atomoxetine. The first one is hypersensitivity; patients known to be hypersensitive to atomoxetine or other constituents of the product should avoid using it. MAO inhibitors (MAOI) should also be taken into account for contraindications. Atomoxetine should not be taken within 2 weeks after discontinuing an MAOI or completely avoid taking MAOI. The same applies to treatment with an MAOI, that it should not be initiated within 2 weeks after discontinuing atomoxetine. Serious and sometimes fatal reactions may occur when atomoxetine and drugs that affect brain monoamine concentration are given concurrently or in close proximity. Examples of reactions are hyperthermia, inflexibility, myoclonus and altered mental states that include extreme agitation, possibly progressing to delirium and coma. Increased risk of mydriasis was associated with Strattera use in clinical trials. Therefore, the use of Strattera is not recommended in patients with narrow angle glaucoma. Patients with pheochromocytoma or a history of pheochromocytoma should not take Strattera because serious reactions (elevated blood pressure and tachyarrhythmia) have been reported in patients who received Strattera. Last but not least, patients with severe cardiac or vascular disorders should not be using Strattera. The only contraindication that is reported in the IMB Micromedex database is prior hypersensitivity to the active compound, reboxetine.
SrSO4 + 2 C → SrS + 2 CO2 About 300,000 tons are processed in this way annually. The metal is produced commercially by reducing strontium oxide with aluminium. The strontium is distilled from the mixture. Strontium metal can also be prepared on a small scale by electrolysis of a solution of strontium chloride in molten potassium chloride:
Sources: en.wikipedia.org
== Early life and education == In 1974, Eaton graduated from Montana State University with a Bachelor of Science in Pre-Medical Sciences. Under the guidance of Curtis Klaassen and John Doull, he earned a Ph.D. in pharmacology and toxicology at the University of Kansas Medical Center in 1978. In 1979, he joined the faculty at the University of Washington after completing a postdoctoral fellowship in toxicology at the same institution after earning his Ph.D.
There were an estimated 106,000 Christian Scientists in the United States in 1990 (427 per million), according to Rodney Stark. In 2009, the church said that for the first time more new members had been admitted from Africa than from the United States, although it offered no numbers. While the Manual of the Mother Church prohibits the church from publishing membership figures, the church does provide the names of Christian Science practitioners (members trained to offer Christian Science prayer on behalf of others). In 1941 there were 11,200 practitioners in the United States, against 965 in 2015 (1,249 worldwide). Stark writes that clusters of practitioners listed in the Christian Science Journal in 1998 were living in the same retirement communities.
==== Alternative-composition breast prosthesis ==== The third category of prosthetic breast includes alternative-composition breast prostheses that featured fillers such as soy oil, polypropylene string, ox cartilage, Terylene wool, ground rubber, silastic rubber, and Teflon-silicone, which are substances harmful to the woman's body.
== History == NMS was known about as early as 1956, shortly after the introduction of the first phenothiazines. NMS was first described in 1960 by French clinicians who had been working on a study involving haloperidol. They characterized the condition that was associated with the side effects of haloperidol "syndrome malin des neuroleptiques", which was translated to neuroleptic malignant syndrome.
Sources: en.wikipedia.org
它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。
分子上的脂肪酸侧链使其与血浆白蛋白结合增强,显著延长循环半衰期。半衰期延长后,稳定血药浓度可在较长的给药间隔内维持,因此常见用法为每周一次。
同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比,临床研究中观察到的血糖与体重变化幅度通常更明显,但各通路的具体贡献比例尚无定论。
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.